Fruquintinib in refractory metastatic colorectal cancer

April 2024

Refractory cancer: cancer that does not respond to treatment

Fruquintinib (Fruzaqla) is a targeted therapy used in the treatment of patients with heavily pretreated metastatic colorectal cancer. It is a treatment that is used when other standard of care treatments such as fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy (if applicable) have failed to control the disease.

Fruquintinib was approved in the United States in November 2023 based on the evidence from the international FRESCO-2 and Chinese FRESCO clinical trials. In both trials, the average overall survival of patients treated with fruquintinib was improved by approximately 3 months compared to the placebo group that received best supportive care.

Currently, fruquintinib is not available in Canada. Colorectal Cancer Canada will be submitting a patient input submission to present patient experience from those that have received fruquintinib for refractory metastatic colorectal cancer to advocate for increased access to this treatment for Canadian patients. We firmly believe that patients should have access to a range of effective therapeutic options, particularly in the metastatic setting. We are currently conducting interview with patients who have received this treatment for refractory metastatic colorectal cancer. If you or someone you know has received this treatment and would like to share your experience, please reach out to CCC at support@colorectalcancercanada.com

Source: https://ascopost.com/issues/march-10-2024/fruquintinib-in-refractory-metastatic-colorectal-cancer/